News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So so so, the pigeons learned to lie by following their proud FDA/CDC who of course led the biggest lie in history of mankind.
Ready for that booster pigeons? Better join the leronlimab crew while their is still time to grab em cheap.
Will those patents expire soon, lmao. Misiu provided the answer direct from the company. What legal had to say shut the naysayers down. And he did not even mention the additional patents that will be filed on the newer long lasting version.
$$CYDY$$ 2024 year of the catalysts. Up we go. We got it, they want it, they will pay to have a nibble.
By Zachary Stieber
May 01, 2024
U.S. Centers for Disease Control and Prevention (CDC) officials found evidence that the Pfizer-BioNTech and Moderna COVID-19 vaccines caused multiple deaths before claiming that there was no evidence linking the vaccines to any deaths, The Epoch Times has learned.
Better go quick and check out Moderna profits way way down, unusual borrowing go on for Puffy Pfuzzy Pfizer. Guess I will go add to my shorts over at Pfizer. Hey fung dirt, how's those dividends holding up? LMAO.
Well , to me this started to look like a serious problem .
I will try not to be bother , I actually feel sorry for him now , Hopefully he will get some help .
And hopefully this quiet for so long from CYDY means that some positive things happening behind that .
GLTU
You must have a very big financial loses when 13 D lost .
Everyone moved on already , except you , you still in this old time , insulting others whose opinion was different then yours at the time .
By now I really feel sorry for you .
And I am hoping that time will come that leronlimab will show to all what a good drug it is .
For now I will suggest to find a good doctor for yourself .
All imo
GLTA longs .
O K , here is transcript with Tyler Blok explanation about our patents .
" So the two most common questions that we get when people ask about IP, and I'm just going to assume this is what people would want to hear by way of an update , is what exactly started to expire by way of IP in 2023, and then generally they want an assurance that the company has some sort of plan, right , or an idea , or is monitoring IP.
So as to the first, in terms of what started to expire in 2023 , the company is very cognizant of what expires and when.
Needless to say , we are a pre-revenue biotech company developing a single molecule . ...........
....................................
....................................
So the underlying molecule of the leronlimab antibody itself started to expire in 2023.
So that is foundational leronlimab .
You heard Jay speak earlier about how long he's been working with the antibody , right ?? There is IP tied to that.
So , as the longer the random at itself has been out in , the IP can only last so long as to the underlying antibodies,
Now , what the company does to build out the next levels of protection is we've gotten IP around the concentrated protein formulation , and those don't start to expire until 2031.
---We've gotten levels of IP protection surrounding the use of leronlimab and the treatment of HIV . That wont start to expire until 2035.
---We have method of action associated with cancer indication and methods of use and those start to expire in 2040.
---And then Covid , we have certain protections that again would start to expire in 2040.
---And then the most recently developed IP surrounding NASH would not even start to expire in 2043.
So , our approach to that IP and what technically started to expire would allow people to use leronlimab antibody for research purposes.
But the practical reality is we we've build up adequate protections around the applications of leronlimab and HIV , Covid , NASH ,
And then there's also some certain methods of action IP that would prevent antibody from substantially competing with us while using the wrong amount of antibodies "
EVERY CENT LOST IS MORE THAN -7% THAT HURTS
APPROACHING THE DREADED 12 CENTS THIS IS SO BAD
The poll is very clear for CYDY.
And it's bad.
LOLOL
Oh I love polls. How many on Ihub are long on CYDY? How many short? Now what we need is a poll to find out how many members of Congress took the jab. What many many not know is that members of Congress did not have to follow any mandates. So did they line up like good lil pigeons. How many took the AstraZeneca jab or before that the J&J jab ... all with heaping praise from the FDA. So how many at the FDA got the jabs? I bet very few. Now, these major pharma players ... all on the big boards but of course previously at one time were mostly on the OTC until they got their amazing approvals from the soul bros at the FDA. Well now bully for the polls and the participants who took the plunge. I feel sorry for those who believed in the system and go duped. See what lack of real DD can do? This is why I trust in CytoDyn and leronlimab, Trust nobody but your own God given brain unless you love eating soylent green. Two thumbs up for Charlton Heston. So pigeons who know it all...belly on up for your next round of jab junk and keep trashing the highly likely miracle drug called leronlimab...the one with no secondary ailments hardly to speak of like maybe a headache or runny nose.
Stroke anyone? Altered menstrual cycle? Long Covid? Heart attacks? Cancer? Compromised immune system? Well, the secondary affects are not pretty for jab junkies where now the uptick of so many conditions especially cancers are skyrocketing since 2021 jabs began. Oh those nasty stats. Oh those nasty polls. Oh, here comes the stroke of FDA genius. https://www.theepochtimes.com/epochtv/vaccine-manufacturer-finally-admits-to-stroke-side-effect-facts-matter-5640630?src_src=enewsnoe&src_cmp=etv1-2024-05-01&est=AAAAAAAAAAAAAAAAdbAmeh0exsTo9bIGsWoXCLt3DMv%2BeZd%2FEugtIdyHPONOLA%3D%3D
Not to worry, in the UK and Canada the taxpayers foot the bill for the lawsuits!
$$CYDY$$ 2024 The year of the catalysts. We got it, they want it, they will pay to collaborate. oh yes, keep digging Sidley! So now, when will the studies and trials resume that the FDA so hastily assisted in protocol development ... as the deadly duo conspired to take the money and run. But who dangled this carrot? Truth will prevail and pigeons will be grounded. In the meantime, get back in line pigeons and bend over for the latest and greatest.
“Your theories are insightful . Completely unhinged from reality “
Well , you really very sure of yourself ,
—You know drug is not good ,
—You know company will BK ,
—You know we will be below 0.10 soon .
If you that smart with everything , I am not sure why you not traveling around the world , but post here ,
you must be super wealthy ..
Or all this is just a stupid talk on the message board ???
All imo
GLTA longs
THAT SINKING FEELING - WELCOME ABOARD THE TITANIC
12 CENTS AHEAD! FULL SPEED!
If you can recognize facts that easy only time will show ..
According to Dr Jay statements , he is very interested in partnerships , and we heard since few years there is an interest to partner with us .
I know our company is without money , this is why we need a good partner , and I for one , know how unusual , good this drug is ,
So I am still optimistic .
I feel the next 12 or so months will give us many answers .
Fingers crossed .
GLTA longs
Hi Monroe ..
Possibly in a proper dose it may work on pigeons too ..
But this is the least of my worries ,
I am waiting for some news about partnership ( s) hopefully in cancer to start …and soon after more ..
GLTU ..
Good article but will it work on pigeons? If so, stock will fly the coop.
https://www.thisoldhouse.com/yards/22756894/best-chicken-coop
Seems they are getting to be the only ones who love the FDA and Pig Pharma
https://endpts.com/pharma-reputation-slips-among-patient-advocacy-groups-according-to-annual-survey/
$2024$ $$$CYDY$$$
13 CENTS DESTROYING BAGHOLDERS - ENJOY THE VIEW
More evidence that CCR5 modulation may inhibit/prevent dementia.
https://www.nature.com/articles/s41419-024-06630-9
GLTA longs.
|
Followers
|
813
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
233768
|
|
Created
|
11/18/05
|
Type
|
Free
|
| Moderators janice shell kgromax | |||
DISCLAIMER:
Securities and Exchange Commission and Department of Justice Investigations
The Company has received subpoenas from the United States Securities and Exchange Commission requesting documents and information concerning, among other matters, leronlimab, the Company’s public statements regarding the use of leronlimab as a potential treatment for COVID-19 and related communications with the FDA, investors, and others, and trading in the securities of CytoDyn. The SEC has informed the Company that this inquiry should not be construed as an indication that any violations of law have occurred or that the SEC has any negative opinion of any person, entity or securities trading activity.
In addition, the Company and certain of its executives have received subpoenas in connection with an investigation being conducted by the United States Department of Justice. The subpoenas seek testimony and/or records concerning, among other matters, leronlimab, the Company’s public statements regarding the use of leronlimab as a potential treatment for COVID-19 and related communications with the FDA, investors, and others, and trading in the securities of CytoDyn.
Securities and Exchange Commission and Department of Justice Investigations
The Company has received subpoenas from the United States Securities and Exchange Commission (“SEC”) and the United States Department of Justice (“DOJ”) requesting documents and information concerning, among other matters, leronlimab, the Company’s public statements regarding the use of leronlimab as a potential treatment for COVID-19, HIV, and triple-negative breast cancer, related communications with the FDA, investors, and others, litigation involving former employees, the Company’s retention of investor relations consultants, and trading in the Company’s securities. Certain Company executives have received subpoenas concerning similar issues and may be interviewed by the DOJ or SEC in the future. The SEC informed the Company that its inquiry should not be construed as an indication that any violations of law have occurred or that the SEC has any negative opinion of any person, entity or security.
The Company is cooperating fully with these non-public, fact-finding investigations, and as of the date of this filing, the Company is unable to predict the ultimate outcome and cannot reasonably estimate the potential possible loss or range of loss, if any.
VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on its HIV program and a full clinical hold on its COVID-19 program in the United States. Further, the Company elected to pause its Brazil COVID-19 trials pending results from its previously scheduled data safety monitoring committee meeting and is in the process of reevaluating the timing of its HIV BLA resubmission.
The Company was not enrolling any new patients in the trials placed on hold in the United States. The partial clinical hold on the HIV program impacts patients currently enrolled in extension trials. These patients will be transitioned to other available therapeutics and no clinical studies can be initiated or resumed until the partial clinical hold is resolved. CytoDyn intends to work closely with the FDA to resolve the partial clinical hold as soon as possible. Under the full clinical hold on the COVID-19 program, no new clinical studies may be initiated until the clinical hold is resolved. The Company is not currently conducting any COVID-19 trials in the United States, as it is evaluating the most optimal programs on which to focus its resources and attention.
“CytoDyn is committed to FDA compliance,” said Scott A. Kelly, M.D., Chief Medical Officer of CytoDyn. “We are evaluating our clinical programs and are working to resolve the issues underlying the clinical holds as soon as possible in close communication with the FDA. We will provide an update when we have additional information.”
Up to 205,652,848 Shares of Common Stock
This prospectus supplement updates, amends and supplements the prospectus dated October 11, 2023, relating to our Registration Statement on Form S-1 (Registration No. 333-272815) (as supplemented or amended from time to time, the “Prospectus”). Capitalized terms used in this prospectus supplement and not otherwise defined herein have the meanings specified in the Prospectus.
This prospectus supplement is being filed to supplement the Prospectus with the following information:
The information in this prospectus supplement includes forward-looking statements relating to, among other things, future clinical trials and our business strategy. The reader is cautioned not to rely on these statements, which are based on our current expectations. Please see below for additional information about risks involving our securities.
This prospectus supplement is not complete without the Prospectus. This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent that the information in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep this prospectus supplement with your Prospectus for future reference. The Prospectus, together with this prospectus supplement, relates to the resale of up to 74,903,789 shares of our common stock, par value $0.001 per share (the “common stock”), and 130,749,059 shares of our common stock underlying certain warrants (collectively, the “Shares”), by the selling stockholders identified in the Prospectus under “Selling Stockholders”.
Our common stock is quoted on the OTCQB of OTC Markets Group, Inc. under the symbol “CYDY.” On February 29, 2024 the closing price of our common stock was $0.2575 per share.
Investing in our securities involves risk. You should carefully consider the risks that we have described under the section captioned “Risk Factors” in the Prospectus on page 8 and in Part II, Item 1A of the 2024 Second Quarter 10-Q before buying our securities.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus supplement is March 1, 2024.
November 3, 2023
November 2023 Letter to Shareholders
Dear Shareholders,
We write to provide an update on CytoDyn Inc. (“CytoDyn” or “Company”), and to thank you for your continued support of the Company.
Throughout our history, CytoDyn has made great strides in developing leronlimab from a single indication molecule into a platform molecule with the potential for multiple therapeutic indications. Through CytoDyn’s investment in clinical trials, we have generated valuable data demonstrating how leronlimab might be used in HIV, oncology, metabolic dysfunction-associated steatohepatitis (“MASH” formerly “NASH”), and metabolic dysfunction-associated steatotic liver disease (“MASLD”). We have also successfully transferred our manufacturing technology allowing us to manufacture leronlimab at scale in preparation for clinical trials and potential FDA approval.
Fiscal year 2023 proved to be a very difficult year for CytoDyn. We had planned to be off clinical hold and back to conducting clinical trials by now. Unfortunately, to date, we have been delayed in our efforts to satisfy the FDA with our clinical hold submission(s). We have embarked on a more comprehensive effort to resolve the FDA’s lingering questions. These efforts include the Company’s hosting of a number of advisory board meetings with key opinion leaders (KOLs). Adding to our delay was the unanticipated medical leave taken by our then President, Dr. Arman creating additional delays in our subsequent resubmission.
However, these unforeseen circumstances provided the time needed to help us gain new insights and understanding of leronlimab in the current HIV treatment environment. Further, we were able to receive and incorporate the perspectives of some of the top HIV KOLs worldwide as to how they believe leronlimab can play a significant role in helping HIV patients, notwithstanding other therapeutic options currently available to patients. As part of this process, the Company engaged various new clinical, regulatory, and medical consultants and advisors with relevant experience and expertise that we believe will continue to benefit the Company for years to come.
The Company has taken necessary actions to position us for near-term and long-term success. During the last fiscal year, the Company implemented significant reductions to its workforce, cash burn rate, and operating expenses, in order to conserve our resources and devote them to critical corporate priorities. In addition to our work in HIV, we have worked with top experts to develop a MASH clinical trial protocol and identify potential MASH pre-clinical combination therapy trial concepts, which trials we believe could be attractive to a partner and position the Company for a greater chance of success within the MASH space. We also began development of a longer-acting therapeutic with a partner who has a very strong and reputable artificial intelligence (“AI”) platform, which we believe may provide significant increases in shareholder value in the years to come. We also believe that the Company is positioned for success in the Amarex litigation. We fully funded Sidley Austin LLP – the preeminent law firm representing the Company in this matter, filed a more-detailed statement of claim, and scheduled a final hearing date (August 12, 2024) in the arbitration.
We understand that CytoDyn’s recent challenges may have tested your confidence. We want to assure you that we remain dedicated to developing important therapeutics that can make a difference in
patients' lives, and at the same time provide value for our shareholders. Again, we are grateful for your ongoing support and trust.
We will continue our efforts to prioritize and execute on goals that will enhance value for all shareholders. Our efforts are focused on successfully completing the resolution of the FDA’s partial clinical hold – having recently made a submission that we hope will be successful – and strengthening our leadership team. Additionally, the Company will be evaluating the various potential indications for leronlimab to maximize the effective and efficient use of our resources. We have always believed leronlimab holds great promise, and we are determined to explore all avenues by which patients and medical practitioners can benefit from its use. We believe that with the improvements we have made and continue to pursue, our company is positioned for long-term success.
We deeply value your investment in CytoDyn and are committed to acting in your best interests. We look forward to continuing to communicate as additional developments occur. We realize the updates above may not answer all the questions you have. We therefore include a November 2023 “Frequently Asked Questions” supplement with this letter. This FAQ supplement is something we intend to update from time to time and it will be posted on the Company’s website in the near future.
Finally, in advance of our upcoming Annual Meeting on November 9, 2023, we want to remind you to submit your votes, if you have not already done so. If you were a shareholder as of September 11, 2023, you are considered a shareholder of record. Notably, the Company has asked for the shareholders’ approval to amend the Company’s Certificate of Incorporation to increase the total number of authorized shares of common stock. This increased share allowance is critical to the ongoing viability of the Company, and we therefore encourage everyone to vote if you have not already done so. If you have any questions or require any assistance in voting your shares, please call the Company’s proxy solicitor, Alliance Advisors LLC, at (833) 814-9456.
Sincerely,
Tanya Durkee Urbach
Board Chair
Note Regarding Forward-Looking Statements
This letter and the accompanying Frequently Asked Questions supplement contain forward-looking statements relating to, among other things, future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and/or our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review the Annual Report on Form 10-K for the fiscal year ended May 31, 2023, including in the sections captioned “Forward Looking Statements” and “Item 1A. Risk Factors”, as later supplemented by our Form 10-Q for the quarter ended August 31, 2023, in the section captioned “Item 1A. Risk Factors”. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments.
AI
